

**DEVELOPMENT OF LABORATORY TESTS FOR ASSESSING
VITAMIN STATUS**

Malina Kate Storer

A thesis submitted for the degree of
Doctor of Philosophy
at the University of Otago, Dunedin,
New Zealand

Date: February 27, 2006

ABSTRACT

Aim

To develop assays for the determination of functional vitamin status and to determine the functional vitamin status of an elderly population. Specifically the focus has been to develop assays to measure the biological concentrations of *N,N*-dimethylglycine and glycine betaine as possible markers of functional folate status.

Background

Functional vitamin deficiencies arise when the tissue concentration of a vitamin derived coenzyme is inadequate this can occur despite normal concentrations of the vitamin in the blood or urine, and leads to lower activity of the vitamin dependent enzyme. The lowered enzyme activity causes changes in the concentrations of metabolites associated with the biochemical pathway catalysed by the enzyme. The amount of vitamin at a tissue level can be determined by measuring these changes. Functional vitamin deficiencies have been associated with many chronic diseases; the relationships between nutrients and disease can be investigated using appropriate assays.

Methods and results

Two new trifluoromethanesulfonate reagents (2-phenanthrenacyl and 6-methoxynaphthacyl) have been synthesised. These reagents form highly fluorescent derivatives with *N,N*-dimethylglycine, glycine betaine and propionylcarnitine. Using 2-phenanthrenacyl triflate as the derivatising reagent the detection limit for glycine betaine is improved from 0.2 μM to 0.04 μM . Optimisation is achieved by changing the solvent, base and water content of the reaction mixture. Polar aprotic solvents are used, with the presence of some water or alcohol tolerated. Suitable bases include the inorganic bases, magnesium hydroxide, silver oxide and lithium phosphate.

The cationic derivatives of *N,N*-dimethylglycine and glycine betaine in plasma are separated by HPLC on an alumina column within 50 minutes. Cation exchange HPLC is carried out using a polar organic solvent containing an aqueous buffer with an organic cation and a hydrophilic anion. Selectivity is affected by the choice of organic solvent and buffer. Increasing the water content and the buffer concentration reduces the retention of the derivatives. Propionylcarnitine can be quantified after separation by HPLC on a

non-encapped strong cation exchange column however the use of this assay to detect functional biotin deficiency has not been validated.

^1H NMR can be used to measure *N,N*-dimethylglycine and glycine betaine in urine. The inter and intra-assay CV's were $< 10\%$ and recoveries were $\geq 97\%$ over a linear range from $50\ \mu\text{M}$ to $1000\ \mu\text{M}$. Limits of detection using ^1H NMR spectroscopy ($15 - 25\ \mu\text{M}$) are higher than HPLC assays, though adequate for the detection of raised concentrations in urine.

Elderly hip fracture patients (aged 65-90) were investigated, as they are known to have poor nutrition compared to health elderly, and would be expected to have associated vitamin deficiencies. A greater percentage of hip fracture patients had insufficient vitamin B_{12} and folate concentrations compared to age matched healthy elderly controls (Folate 55% and 32% $< 120\ \text{pM}$, Vitamin B_{12} 7% and 5% $< 8.5\ \text{nM}$). The results for other analytes are difficult to interpret because of the affects of recent trauma. In the control population glycine betaine predicts total homocysteine concentrations (multiple linear regression $-0.055\ \text{P} = 0.099$) and is a stronger predictor of folate than total homocysteine. The ratio of the concentrations of *N,N*-dimethylglycine/glycine betaine was not significantly associated with folate status.

Conclusion

The concentrations of *N,N*-dimethylglycine and glycine betaine in plasma can be measured by HPLC, and in urine by ^1H NMR. In healthy elderly there is a high prevalence of vitamin deficiency. The ratio of *N,N*-dimethylglycine/glycine betaine is not an appropriate marker of functional folate status, however the associations between glycine betaine and homocysteine metabolism require further investigation.

PUBLICATIONS ARISING FROM THIS THESIS

McEntyre, C. J., M. Lever and M. K. Storer (2004). "A High Performance Liquid Chromatographic Method for the Measurement of Total Carnitine in Human Plasma and Urine." Clinica Chimica Acta **344**: 123-130.

Happer, D. A. R., C. M. Hayman, M. K. Storer and M. Lever (2004). "Aracyl Triflates as Derivatizing Agents for Biological Betaines." Australian Journal of Chemistry **57**: 467-472.

Mishra, S., M. K. Storer, C. M. T. Sherwin and J. G. Lewis (2005). "A Simple Binding Assay for the Direct Determination of Biotin in Urine." Clinica Chimica Acta **360**: 60-66.

Storer, M. K. and M. Lever (2006). "Aracyl Triflates for Preparing Fluorescent and UV Absorbing Derivatives of Unreactive Carboxylates, Amines and Other Metabolites." Analytica Chimica Acta **558**: 319-325.

Storer, M. K., C. J. McEntyre and M. Lever (2006). "Separation of Cationic Aracyl Derivatives of Betaines and Related Compounds." Journal of Chromatography A **1104**: 263-271.

Lee, M. B., M. K. Storer, J. W. Blunt and M. Lever (2006). "Validation of ¹H NMR Spectroscopy as an Analytical Tool for Methylamine Metabolites in Urine." Clinica Chimica Acta **365**: 264-269.

ACKNOWLEDGEMENTS

The work described in this thesis would not have been accomplished without guidance, support and encouragement from a large number of people. In particular I owe a huge thanks to my supervisors; Dr Alan Happer for advice on all things chemistry, Professor Peter George for supporting my research at Canterbury Health Laboratories and his clinical biochemistry expertise, Professor Stephen Chambers for his enthusiasm regarding the clinical study and Dr Michael Lever for being a wealth of information, guidance and advice regarding all aspects of this project. You have all had a huge part to play in this accomplishment and I am extremely grateful.

I would like to thank John Lewis and Suman Mishra in the Steroid Laboratory at Canterbury Health Laboratories for the biotin assay development, Tim Wilkinson for consultation during the initial conception of the hip fracture study and Elisabeth Wells for invaluable statistical advice. Phil Zakaria, Paul Haddad and all of the team at the Australian Centre for Research on Separation Science, deserve thanks for helping me come to terms with capillary electrophoresis. My thanks to the “Men of Steel” for their assistance during my time in the Chemistry department. I would also like to thank Steve Brennan for his assistance with mass spectrometry and Martin for his NMR spectroscopy expertise.

I am grateful to the willing patients and volunteers who participated in the clinical study. Additionally I would like to thank the blood collection staff and the staff of wards 18 and 19 at Christchurch Hospital for their cooperation. I am indebted to Chris Budgen, Lesney Stuart, Charles Hawes, Sue Carnoutsos, Linda Pike and the other staff in the respective sections at Canterbury Health Laboratories for many of the analyses performed on the samples.

Financial assistance is invaluable in an undertaking such as this and I am grateful to Canterbury Health Laboratories, the Foundation for Research Science and Technology, and the Todd Foundation for their contributions.

Many thanks to the people that have put up with me every day in the lab; Sarah M for tolerating me in the confined space of our office at all times but especially during the stressful writing-up process, Chris M for keeping the place running, Wendy, Madhu, Martin, and Sandy S for the laughs and the moral support: it's been a pleasure to work with you all. Sandy W, Chris S, Julia and Linda thanks for sharing your lab space. To my summer students Sarah

L, Catherine, and Ange thank you for your great work and entertainment over the summer months.

Thanks to the people who helped me stay sane; Marie, Sarah L, and Anna for understanding exactly what I was going through, along with Kate and Jasmine for distracting me, entertaining me, planning with me and counseling me. My thanks to Matt for putting up with me, and Michaela, and everyone else who's flattered with me for their support.

My biggest thanks and all my love to my family; to Heath and Briar for your support, even if you didn't think I was ever going to finish University and to my parents - thanks for having me, for your unwavering support, encouragement and love. I couldn't have done this without you.

In closing I would like to thank the anonymous author of my email quote... thank you for keeping it all in perspective!

"Life should NOT be a journey to the grave with the intention of arriving safely in an attractive and well-preserved body, but rather to skid in sideways, Champagne in one hand, strawberries in the other, body thoroughly used up, totally worn out & screaming 'WOO HOO - What a ride!'"

TABLE OF CONTENTS

Abstract	ii
Publications arising from this thesis.....	iv
Acknowledgements	v
Table of contents	vii
Table of illustrations.....	xii
List of abbreviations	xvii
1 AN OVERVIEW OF VITAMIN DEFICIENCIES AND METHODS FOR THE DETERMINATION OF VITAMIN STATUS.....	2
1.1 History and significance of vitamins	2
1.1.1 The history of vitamins.....	4
1.2 Causes of vitamin deficiency.....	7
1.3 Functional vitamin deficiencies and the consequences	9
1.3.1 Vitamins and the risk of cardiovascular disease.....	9
1.3.2 Vitamins concentrations and cancer risk.....	12
1.3.3 Vitamin status and the connection with pregnancy complications	13
1.3.4 The influence of vitamins status on neurological disorders	14
1.3.5 Vitamins and the risk of hip fracture.....	15
1.4 Determining vitamin status.....	16
1.4.1 Determining thiamine status.....	20
1.4.2 Measuring biotin concentrations in biological samples	23
1.4.3 Measuring folate concentrations in biological samples	26
1.4.4 Determining vitamin B ₁₂ concentrations.....	29
1.4.5 Correcting vitamin deficiencies.....	33
1.5 Aims of this work	34
1.6 References for chapter one	35

2	PREPARATION AND USE OF ARACYL TRIFLATE REAGENTS FOR THE DERIVATISATION OF BETAINES	43
2.1	Introduction	43
2.2	Preparation of derivatising reagents	46
2.3	Spectroscopic properties of the reagents and derivatives	49
2.4	Specificity of the derivatisation reaction	54
2.4.1	Derivatisation of the carboxyl group of betaines	56
2.4.2	Derivatisation of amines.....	56
2.4.3	Derivatisation of <i>N,N</i> -dimethylglycine	57
2.4.4	Other derivatives	58
2.5	Optimisation of the derivatisation reaction	59
2.5.1	Choice of derivatisation solvent	59
2.5.2	Choice of base for derivatisation.....	63
2.5.3	Effect of water and extra base on derivatisation	65
2.5.4	Limits of detection.....	66
2.6	Conclusions	67
2.7	Experimental.....	69
2.8	References for chapter two	76
3	OPTIMISATION OF AN HPLC ASSAY FOR THE SEPARATION OF GLYCINE BETAINE AND <i>N,N</i> -DIMETHYLGLYCINE IN PLASMA.....	79
3.1	Biological importance of betaines and related compounds.....	79
3.1.1	Glycine betaine and <i>N,N</i> -dimethylglycine	81
3.2	Methods for measuring glycine betaine and <i>N,N</i> -dimethylglycine in plasma and urine	86
3.2.1	Use of HPLC to measure betaines.....	89
3.3	Optimisation of an HPLC assay to measure glycine betaine and <i>N,N</i> -dimethylglycine	90
3.3.1	Samples	90
3.3.2	Column choice.....	91
3.3.3	Choice of organic solvent.....	93
3.3.4	Choice of buffer.....	94
3.3.5	Buffer concentration.....	96
3.3.6	Water content	97
3.3.7	Conditions used for the separation of glycine betaine and <i>N,N</i> -dimethylglycine in plasma.....	98
3.3.8	Linearity	99

3.3.9	Precision and accuracy studies	100
3.4	Discussion.....	101
3.5	Experimental.....	102
3.6	References for chapter three	104
4	VALIDATION OF A ¹ H NMR ASSAY FOR GLYCINE BETAINE AND <i>N,N</i> -DIMETHYLGLYCINE IN URINE.....	108
4.1	Use of ¹ H NMR spectroscopy to determine biological concentrations of betaines.....	108
4.2	Validation of an ¹ H NMR assay for glycine betaine and <i>N,N</i> -dimethylglycine.....	110
4.2.1	Methods	110
4.3	Results	111
4.3.1	Precision study.....	112
4.3.2	Accuracy.....	112
4.3.3	Linearity	113
4.4	Discussion.....	114
4.5	Experimental.....	116
4.6	References for chapter four	117
5	DEVELOPMENT OF CAPILLARY ELECTROPHORESIS ASSAYS FOR BETAINES, AND THIAMINE SPECIES IN BIOLOGICAL SAMPLES	119
5.1	Introduction to capillary electrophoresis	119
5.1.1	Detection methods used in capillary electrophoresis assays.....	120
5.1.2	Capillary specifications	121
5.1.3	Calculating analyte mobility.....	121
5.1.4	Selection of running voltage.....	122
5.1.5	Background electrolyte choice	122
5.1.6	Capillary coatings.....	123
5.1.7	The use of additives.....	123
5.1.8	Micellar electrokinetic chromatography.....	124
5.2	Previous use of capillary electrophoresis for the separation of betaines.....	126
5.3	Separation of betaines using capillary electrophoresis.....	128
5.3.1	Samples	128
5.3.2	Selection of coating for the capillary.....	129
5.3.3	Choice of buffer type and pH.....	131
5.3.4	Use of cyclodextrins	133

5.3.5	Use of organic modifiers	136
5.3.6	Use of phytic acid.....	138
5.3.7	Calculation of mobility.....	139
5.4	The final separation	140
5.5	The use of capillary electrophoresis to measure thiamine species	142
5.6	Development of a capillary zone electrophoresis method for thiamine species.....	144
5.6.1	The sample	144
5.6.2	Capillary zone electrophoresis conditions.....	146
5.6.3	Detection	148
5.6.4	Final separation of thiamine species	149
5.7	Conclusions	150
5.8	Experimental.....	151
5.9	Reference for chapter five	153
6	DEVELOPMENT OF ANALYTICAL METHODS FOR DETERMINING BIOTIN STATUS.....	155
6.1	Biotin, the forgotten vitamin	155
6.1.1	Methods for the quantification of biotin status	156
6.1.2	Propionylcarnitine as a potential marker of functional biotin status.....	157
6.1.3	Measuring propionylcarnitine	159
6.2	A novel binding assay for biotin.....	161
6.2.1	Methods	161
6.2.2	Standard curve	162
6.2.3	Precision study.....	163
6.2.4	Accuracy.....	163
6.2.5	Normal biotin excretion.....	163
6.3	Biotin binding assay discussion.....	164
6.4	Development of an HPLC assay for propionylcarnitine	165
6.4.1	Sample preparation.....	165
6.4.2	Limits of detection.....	166
6.4.3	Method validation.....	166
6.4.4	Precision and accuracy study.....	167
6.4.5	Linearity	168
6.5	Discussion of propionylcarnitine assay	169
6.6	Conclusions	170

6.7	Experimental.....	1718
6.8	References for chapter six	173
7	COMPARISON OF FUNCTIONAL VITAMIN STATUS IN ELDERLY NEW ZEALANDERS WITH AND WITHOUT HIP FRACTURE.....	1763
7.1	Vitamin deficiency in the elderly	176
7.2	Vitamin status of elderly hip fracture patients.....	180
	7.2.1 Population recruitment	180
	7.2.2 Sample collection	180
	7.2.3 Statistical analyses.....	180
	7.2.4 Graphs and tables	181
7.3	Results	182
	7.3.1 Population distribution	183
	7.3.2 Laboratory test results	183
	7.3.3 Vitamin B ₁₂ and folate concentrations	185
	7.3.4 Homocysteine and methylmalonic acid concentrations	186
	7.3.5 Glycine betaine and <i>N,N</i> -dimethylglycine concentrations	187
	7.3.6 <i>N,N</i> -Dimethylglycine/ glycine betaine ratio.....	188
	7.3.7 Carnitine concentrations.....	188
	7.3.8 Statistical analysis	188
7.4	Discussion.....	193
	7.4.1 Folate status	194
	7.4.2 Vitamin B ₁₂ status	195
	7.4.3 Homocysteine concentrations.....	196
	7.4.4 Betaine concentrations	197
	7.4.5 Markers of functional vitamin deficiency	197
	7.4.6 Fractures and vitamins and markers.....	199
7.5	Conclusions	201
7.6	Experimental.....	204
7.7	References for chapter seven.....	206
8	CONCLUSIONS AND FUTURE WORK.....	210
8.1	Conclusions and future work.....	210
8.2	References for chapter eight.....	215

TABLE OF ILLUSTRATIONS

1	AN OVERVIEW OF VITAMIN DEFICIENCIES AND METHODS FOR THE DETERMINATION OF VITAMIN STATUS.....	2
	Table 1.1 Vitamin derived coenzymes and their biological roles.....	3
	Table 1.2 Dates of significant discoveries of vitamins	5
	Table 1.3 Symptoms of clinical vitamin deficiency	6
	Figure 1.1 Homocysteine metabolism	10
	Table 1.4 Reference ranges for vitamin assays.....	17
	Figure 1.2 A schematic vitamin dependant pathway	19
	Figure 1.3 Thiamine dependent transketolase pathway.....	21
	Figure 1.4 Biotin and Biotin metabolites.....	23
	Figure 1.5 β -Methylcrotonyl-CoA carboxylase biotin dependant pathway	25
	Figure 1.6 Folate species and the 1-carbon groups transferred	27
	Figure 1.7 Vitamin B ₁₂ dependent pathway.....	31
2	PREPARATION AND USE OF ARACYL TRIFLATE REAGENTS FOR THE DERIVATISATION OF BETAINES	43
	Table 2.1 Spectroscopic properties of the starting materials	46
	Figure 2.1 Structures of aracyl triflate derivatising reagents.....	47
	Scheme 2.1 Triflate reagent synthesis	48
	Table 2.2 Spectroscopic properties of the reagent in propan-2-ol.....	49
	Figure 2.2 2-(2,3-Naphthalimino) ethyl triflate.....	49
	Table 2.3 Spectroscopic properties of the derivatives in propan-2-ol	50
	Table 2.4 Fluorescence properties of reagents and derivatives in acetonitrile	51
	Figure 2.3 Fluorescence properties of the 2-phenanthrenacyl triflate reagent and its glycine betaine derivative in different solvents.....	52
	Scheme 2.2 Derivatisation of glycine betaine by 2-naphthacyl triflate.....	54
	Table 2.5 Structures of compounds derivatised and masses of 2-naphthacyl derivatives	55
	Figure 2.4 Variation of derivative yields with time.....	56
	Figure 2.5 HPLC showing <i>N,N</i> -dimethylglycine mono derivative (bold), <i>N,N</i> -dimethylglycine derivatisation mixture.....	57
	Figure 2.6 HPLC trace showing derivative formed when acetonitrile used as solvent.....	59
	Table 2.6 Relative efficiencies of derivatisation in different solvents	60
	Figure 2.7 HPLC trace showing peaks caused by impurities in solvent.....	61

Figure 2.8 HPLC trace showing multiple <i>N,N</i> -dimethylglycine peaks in dimethoxyethane	61
Table 2.7 Solvents used for derivatisation with triflate reagents	62
Figure 2.9 HPLC trace showing derivatisation with alternative base	63
Figure 2.10 HPLC trace showing peaks resulting from impurities from resin bases	63
Table 2.8 Relative efficiency of derivatisation with different bases	64
Table 2.9 Limits of detection	66
Table 2.10 Best derivatisation conditions	67
3 OPTIMISATION OF AN HPLC ASSAY FOR THE SEPARATION OF GLYCINE	
BETAINE AND <i>N,N</i> -DIMETHYLGLYCINE IN PLASMA	79
Figure 3.1 Structures of betaines and related compounds	79
Figure 3.2 Homocysteine remethylation pathways	82
Table 3.1 Biological concentrations of glycine betaine and <i>N,N</i> -dimethylglycine in plasma and urine	87
Table 3.2 Limits of detection of common assays for glycine betaine and <i>N,N</i> -dimethylglycine	88
Figure 3.1 Separation of betaine 2-naphthacyl ester derivatives by HPLC using four different columns	92
Table 3.1 Choice of column	93
Table 3.2 Choice of base	95
Table 3.3 Effect of salt concentration in mobile phase	96
Table 3.4 Effect of water in mobile phase	97
Figure 3.2 HPLC traces of separation of glycine betaine and <i>N,N</i> -dimethylglycine in plasma with Alumina and strong cation exchange Phenosphere columns	98
Table 3.5 Conditions for separation of glycine betaine and <i>N,N</i> -dimethylglycine in plasma	99
Table 3.6 Linearity of the assay	99
Table 3.7 Results of the precision studies	100

4	VALIDATION OF A ¹ H NMR ASSAY FOR GLYCINE BETAINE AND <i>N,N</i> -DIMETHYLGLYCINE IN URINE.....	108
	Figure 4.1 ¹ H NMR spectra of spiked (300 μM) urine.....	110
	Table 4.1 Chemical shifts of the metabolites analysed.....	112
	Table 4.2 Results of precision study of glycine betaine and <i>N,N</i> -dimethylglycine in urine	112
	Figure 4.2 Standard curves for <i>N,N</i> -dimethylglycine and glycine betaine measured by ¹ H NMR Spectroscopy.	113
5	DEVELOPMENT OF CAPILLARY ELECTROPHORESIS ASSAYS FOR BETAINES, AND THIAMINE SPECIES IN BIOLOGICAL SAMPLES	119
	Figure 5.1 Schematic of CE.....	120
	Equation 5.1 Apparent mobility.....	121
	Equation 5.2 Total mobility.....	121
	Figure 5.2 Micellar electrokinetic chromatography.....	124
	Figure 5.3 UV spectra.....	129
	Figure 5.4 Effect of changing the capillary coating.....	130
	Figure 5.5 Structure of phytic acid (5.1).....	131
	Figure 5.6 Effect of changing the pH	132
	Figure 5.7 Effect of change of buffer.....	133
	Figure 5.8 Effect of neutral cyclodextrin.....	134
	Figure 5.9 Effects of mixed cyclodextrins.....	135
	Figure 5.10 Effect of methanol	136
	Figure 5.11 Effect of NaCl	137
	Figure 5.12 Effects of phytic acid.....	138
	Figure 5.13 Mobility of analytes.....	139
	Figure 5.14 Best Separation.....	140
	Figure 5.15 Structures.....	144
	Table 5.1 Fluorescent properties of the thiochrome derivatives (pH 9.2)	145
	Figure 5.16 Fluorescence scan of thiamine pyrophosphate	145
	Figure 5.17 UV properties	146
	Figure 5.18 Affect of sodium dodecyl sulfate on separation.....	147
	Figure 5.19 Peak areas with UV and fluorescence detection	148

6	DEVELOPMENT OF ANALYTICAL METHODS FOR DETERMINING BIOTIN STATUS.....	155
	Figure 6.1 Propionyl CoA carboxylase metabolism.....	157
	Figure 6.2 Structure of propionylcarnitine	158
	Figure 6.3 Typical standard curve for biotin-binding assay.....	162
	Table 6.1 Results of precision study of biotin in urine.....	163
	Table 6.2 Recoveries of biotin in urine.....	163
	Table 6.3 Concentration of biotin in urine.....	163
	Table 6.4 Limits of detection for derivatisation in different solvents	166
	Figure 6.4 Separation of propionylcarnitine in urine.....	167
	Table 6.5 Results of the precision study for propionylcarnitine.....	167
	Figure 6.5 Linearity of the propionylcarnitine method.....	168
	Table 6.6 Limits of detection for propionylcarnitine.....	169
7	COMPARISON OF FUNCTIONAL VITAMIN STATUS IN ELDERLY NEW ZEALANDERS WITH AND WITHOUT HIP FRACTURE.....	176
	Table 7.1 Age and sex distribution of populations	182
	Table 7.2 Laboratory results	183
	Table 7.3 Prevalence of abnormal concentrations	183
	Table 7.4 Vitamins and markers results.....	184
	Table 7.5 Prevalence of abnormal concentrations of vitamins and markers	184
	Figure 7.1 Vitamin B ₁₂ concentrations in #NOF and control populations	185
	Figure 7.2 Folate concentrations in #NOF and control populations.....	185
	Figure 7.3 Total homocysteine concentrations in #NOF and controls	186
	Figure 7.4 Methylmalonic acid concentrations in #NOF and controls.....	186
	Figure 7.5 Glycine betaine concentrations in #NOF and controls.....	187
	Figure 7.6 <i>N,N</i> -Dimethylglycine concentrations in #NOF and controls	187
	Figure 7.7 <i>N,N</i> -Dimethylglycine/ glycine betaine ratio in #NOF and controls.....	188
	Figure 7.8 Carnitine concentrations in #NOF and controls	188
	Table 7.6 Spearman correlation coefficients for control and #NOF populations.....	189
	Table 7.7 Predictors of total homocysteine in control and #NOF population	190
	Table 7.8 Predictors of methylmalonic acid in control and #NOF population.....	191
	Table 7.9 Predictors of glycine betaine in control and #NOF population	191
	Table 7.10 Predictors of <i>N,N</i> -dimethylglycine in control and #NOF population.....	192

Table 7.11 Predictors of <i>N,N</i> -dimethylglycine/glycine betaine ratio in control and #NOF population.....	192
--	-----

LIST OF ABBREVIATIONS

#NOF	fractured neck of femur
^1H NMR	proton nuclear magnetic resonance
$^{\circ}\text{C}$	degrees celsius
CE	capillary electrophoresis
EDTA	<i>N,N,N,N</i> -ethylenediamine tetraacetic acid
ELISA	enzyme linked immunosorbent assay
ESI MS/MS	electrospray ionisation tandem mass spectrometry
GC-MS	gas chromatography mass spectrometry
HIV	human immunodeficiency virus
HPLC	high pressure liquid chromatography
hr.	hour
LC-MS/MS	liquid chromatography tandem mass spectrometry
Lihep	lithium heprin
M	molL^{-1}
min	minutes
NAD^+	nicotinamide adenine dinucleotide
NADH	reduced nicotinamide adenine dinucleotide
NMR	nuclear magnetic resonance
pK_a	log of the acid dissociation constant
pH	negative log of the hydrogen ion concentration
r	correlation coefficient
RNA	ribonucleic acid
SD	standard deviation
UV	ultra violet
v/v	volume to volume
λ	wavelength